Skin Lesions May Be Aggressive Tumors-in-Waiting


Breast cancer patients are at heightened risk for a cancer that orgininates in the lining of the blood vessels, and researchers may have found a precursor.

Physicians have long noticed that breast cancer patients who have had surgery or radiation therapy have an heightened risk of developing angiosarcoma, a rare type of cancer that originates in the lining of the blood vessels.

Now, researchers at Loyola University Health System in Maywood, Ill., have focused in on a finding that could be a possible precursor to angiosarcoma. With further research this finding could lead to more definitive markers that could predict those who are most likely to develop the disease. Angiosarcoma is a malignant, rapidly growing, highly invasive type of cancer that has a high mortality rate.

In a case study published in the Journal of the American Academy of Dermatology, researchers at Loyola identified what at first appeared to be only a tiny bruise on the right breast of a 63-year-old woman. Four years prior the woman had had a lumpectomy in the breast and radiation therapy for cancer. She had also had chemotherapy and hormone therapy.

“Normally, when you see a benign-appearing vascular lesion, you probably would pass it up,” said Dr. Joshua Mandrell, a dermatologist who co-authored the report. “But given her history, we biopsied it and it did show that it was an atypical vascular lesion.”

Atypical vascular lesions are abnormal vascular growths that are thought to form in response to trauma, such as that caused by surgery and radiation therapy, according to the study. The lesions are so rare that few medical professionals are aware of their existence. There are also no well defined prognosis factors or treatment guidelines for them.

“Atypical vascular lesions are not completely benign blood vessel growths and are not angiosarcoma. They are right in the middle. They are atypical enough that we suggest in our study that they warrant treatment,” Mandrell said. “The thought is that they could potentially become angiosarcomas.”

As a precaution, the patient’s lesion and a significant amount of tissue surrounding it was surgically removed.

“We wanted to make sure that nothing was left that could progress to an angiosarcoma,” Mandrell said.

The study concludes that the focus of future research should be on finding markers to detect which type of atypical vascular lesions are more likely to lead to an angiosarcoma.

“This is probably where most of the research should be done,” Mandrell said. “Anybody who has had radiation has changes in their skin. It was probably radiation in combination with the surgery for the cancer that led to the development of this entity. The main question is, ‘Are there special markers or other histological features underneath the microscope that would suggest that an atypical vascular lesion is worse and more likely to develop into an angiosarcoma and another one is not?’ That’s still not well defined.”

The study also concludes that the medical community needs to heighten its surveillance of the skin of patients who have a history of surgery and radiation therapy for breast cancer.

“Even benign-appearing lesions can be serious given that medical history,” Mandrell said. “Dermatologists and primary care physicians should be looking at the skin for any changes in this patient population.”

Source: Loyola University Health System

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.